Abstract Novel coronavirus infections 2019 (COVID-19) associated hyperinflammatory
syndromes are well-defined clinical conditions and have a potential risk for severe infection …

We read with great interest Dr. Felsenstein review about SARS-CoV2 available treatment
options [1]. It is reasonable to try to stop the ominous cycle established by lymphocytes …

Primary and secondary haemophagocytic lymphohistiocytosis (HLH) are hyperferritinaemic
hyperinflammatory syndromes with a common terminal pathway triggered by different …

In this study, laboratorial parameters of hospitalized novel coronavirus (COVID‐19) patients,
who were complicated with severe pneumonia, were compared with the findings of cytokine …

COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes
only mild symptoms in the majority of the cases, while immunologic complications such as …

Abstract Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-
inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine …

Abstract Coronavirus disease 2019 (SARS-CoV2) is an active global health threat for which
treatments are desperately being sought. Even though most people infected experience mild …

In December 2019, a new strain of coronavirus, severe acute respiratory syndrome–
coronavirus 2 (SARS-CoV-2), was recognized to have emerged in Wuhan, China. Along …

Hemophagocytic lymphohistiocytosis (HLH) is a disease that can affect both children and
adults. HLH can be categorized as primary or secondary. Secondary HLH (sHLH) may be …

The clinical features of COVID-19 have a considerable range from a mild illness to severe
disease. Underlying pathophysiological mechanisms of the rapidly progressive, and often …